OPEN ACCESS

ISSN: 2835-9496

Hassan M, et al. (2024): 446
DOI: 10.47991/2835-9496/AJCMR-133

Research Article

American Journal of Clinical and Medical Research

Targeting Cutaneous Immune Responses for Cardiovascular Disease Prevention and Therapy

Muhammad Hassan[1], MD, Kelly Frasier[1*], DO, MS, Vivian Li[2], MMS, Saad Javaid[3], MD

[1]Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY
[2]Lake Erie College of Osteopathic Medicine, Erie, PA
[3]Wyckoff Heights Medical Center, Brooklyn, NY

[*]**Corresponding author:** Kelly Frasier, DO, MS, Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY. Email: kellymariefrasier@gmail.com

Citation: Hassan M, Frasier K, Li V, Javaid S (2024) Targeting Cutaneous Immune Responses for Cardiovascular Disease Prevention and Therapy. Ameri J Clin Med Re: AJCMR-133.

Received Date: 14 May, 2024; **Accepted Date:** 22 May, 2024; **Published Date:** 27 May, 2024

Abstract

The complex interplay between the skin immune system and cardiovascular health presents a compelling avenue for investigation in the realm of preventive and therapeutic interventions for cardiovascular diseases. Current literature highlights the significance of immune-mediated mechanisms in cardiovascular pathophysiology, suggesting that modulating cutaneous immune responses could offer novel strategies for mitigating cardiovascular risk and enhancing patient outcomes. While preliminary evidence supports the potential of immunomodulatory agents and interventions targeting skin inflammation and immune dysregulation, further research is warranted to explore the underlying molecular pathways and validate their efficacy in clinical settings. Future studies should focus on delineating the specific mechanisms through which cutaneous immune modulation influences cardiovascular health, thereby bridging the gap between dermatology and cardiology and paving the way for innovative approaches to cardiovascular disease prevention and therapy.

Introduction

The skin, our body's largest organ, is not only a physical barrier protecting against external threats but also hosts a complex immune system crucial for maintaining homeostasis and defending against pathogens. Recent studies have shed light on the intricate interplay between the skin immune system and cardiovascular health, suggesting a bidirectional relationship between cutaneous immunity and cardiovascular diseases (CVDs). While traditional risk factors such as hypertension, dyslipidemia, and diabetes mellitus are well-established contributors to CVD development, emerging evidence suggests that immune-mediated mechanisms, particularly those involving the skin, may play a significant role in cardiovascular pathophysiology. This paper aims to review the current literature on the role of cutaneous immune modulation in cardiovascular health, explore potential therapeutic interventions targeting skin immunity for cardiovascular disease prevention and therapy, discuss areas for future research, and provide insights into the implications of these findings for clinical practice.

Recent research has highlighted the role of inflammatory pathways and immune cell activation in the pathogenesis of cardiovascular diseases (CVDs). For instance, studies have shown that chronic low-grade inflammation, characterized by elevated levels of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), contributes to endothelial dysfunction, plaque formation, and thrombosis, thereby promoting atherosclerosis and increasing the risk of cardiovascular events [1]. Moreover, immune cells, including T cells and macrophages, infiltrate atherosclerotic plaques, where they release pro-inflammatory mediators and exacerbate vascular inflammation [2]. These findings underscore the importance of immune-mediated processes in cardiovascular pathophysiology and suggest that targeting inflammation and immune dysregulation could represent a promising approach for CVD prevention and therapy.

Furthermore, emerging evidence suggests that the skin immune system plays a crucial role in systemic immune responses and cardiovascular health. The skin is rich in immune cells, including dendritic cells, macrophages, and T cells, which serve as sentinels of the immune system and play key roles in initiating and regulating immune responses [3]. These cutaneous immune cells can interact with circulating immune cells and modulate systemic inflammation, thereby influencing cardiovascular risk. Moreover, the skin microbiota, which comprises diverse microbial communities inhabiting the skin surface, has been implicated in immune regulation and may impact cardiovascular health [4]. Dysbiosis of the skin microbiota, characterized by alterations in microbial composition and diversity, has been associated with inflammatory skin conditions and systemic inflammation, which are known risk factors for CVD [5]. Understanding the role of the skin immune system and microbiota in cardiovascular health could provide insights into novel therapeutic targets for CVD prevention and management.

In addition to its role in systemic immune regulation, the skin serves as a target organ for various cardiovascular risk factors and diseases. For example, hypertension, a major risk factor for CVD, has been associated with cutaneous manifestations such as increased skin vascular resistance and impaired microcirculation [6]. Similarly, diabetes mellitus can lead to diabetic dermatopathy, characterized by cutaneous manifestations such as necrobiosis lipoidica, diabetic foot ulcers, and diabetic dermopathy, which may serve as markers of underlying microvascular complications and increased cardiovascular risk [7]. Understanding the bidirectional

relationship between cardiovascular risk factors and cutaneous manifestations could provide insights into shared pathophysiological mechanisms and facilitate early detection and management of cardiovascular complications in at-risk individuals.

Discussion

Numerous studies have demonstrated the involvement of immune-mediated processes in the pathogenesis of atherosclerosis, the underlying cause of most CVDs. The activation of inflammatory pathways within the vessel wall contributes to endothelial dysfunction, plaque formation, and ultimately, cardiovascular events. Interestingly, recent research has implicated the skin immune system in modulating systemic inflammation and cardiovascular risk. For example, psoriasis, a chronic inflammatory skin disorder, has been associated with an increased prevalence of CVD and cardiovascular events, independent of traditional risk factors. Additionally, studies have shown that patients with atopic dermatitis, another inflammatory skin condition, may have a higher risk of developing CVD. These findings suggest that targeting cutaneous immune responses could represent a promising approach for managing cardiovascular risk and improving patient outcomes.

Several potential mechanisms have been proposed to explain the link between cutaneous immune modulation and cardiovascular health. One proposed mechanism involves the release of pro-inflammatory cytokines and chemokines from the skin, which can enter the circulation and promote vascular inflammation and atherosclerosis. Moreover, dysregulation of the skin microbiota, which plays a crucial role in immune homeostasis, has been implicated in the pathogenesis of CVD. Alterations in the skin microbiome composition may lead to systemic inflammation and endothelial dysfunction, contributing to CVD development. Additionally, the skin is rich in immune cells, such as dendritic cells, macrophages, and T cells, which can interact with circulating immune cells and influence systemic immune responses. Modulating these cutaneous immune cells through targeted interventions may have far-reaching effects on cardiovascular health.

Several studies have investigated the potential therapeutic benefits of immunomodulatory agents in the management of CVD. For example, biologic therapies targeting pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) inhibitors, have shown promise in reducing cardiovascular risk in patients with inflammatory conditions like psoriasis and rheumatoid arthritis. Similarly, interventions aimed at restoring skin barrier function and rebalancing the skin microbiota, such as topical emollients and probiotics, have been proposed as potential strategies for preventing CVD progression. However, while these preliminary findings are encouraging, further research is needed to understand the specific mechanisms underlying the effects of cutaneous immune modulation on cardiovascular health and validate the efficacy of these interventions in clinical settings.

Recent studies have highlighted the role of specific immune cell subsets in linking cutaneous immunity to cardiovascular health. For instance, regulatory T cells (Tregs), a subset of CD4+ T cells known for their immunosuppressive functions, have been implicated in the modulation of atherosclerosis. Tregs can infiltrate atherosclerotic lesions and suppress local inflammation, thereby inhibiting plaque progression and stabilizing vulnerable plaques. Moreover, Tregs have been shown to play a crucial role in maintaining immune tolerance and preventing autoimmune responses, which are implicated in the pathogenesis of CVD. Dysregulation of Treg function in the skin and systemic circulation may contribute to chronic inflammation and atherosclerosis. Thus, strategies aimed at enhancing Treg activity or restoring Treg function in the skin may hold promise for attenuating cardiovascular risk.

The systemic impact of localized immune responses, particularly in the context of autoimmune skin diseases, offers a unique lens through which to understand cardiovascular health. Conditions such as lupus erythematosus that manifest in the skin not only provide models for studying systemic inflammation but also highlight the intricate connections between immune dysregulation and CVDs. Lupus erythematosus, particularly systemic lupus erythematosus (SLE), serves as a prime example of how autoimmune diseases can influence cardiovascular risk. SLE is characterized by chronic inflammation and autoantibody production, with cutaneous manifestations being one of the most common clinical features. Studies have shown that patients with SLE have a significantly increased risk of developing CVDs, including atherosclerosis, myocardial infarction, and stroke, compared to the general population [8,9]. This increased risk is not limited to the attributions of traditional cardiovascular risk factors. Interestingly, the chronic, systemic inflammatory state driven by autoimmune activity in SLE promotes endothelial dysfunction, oxidative stress, and lipid abnormalities, which are key contributors to atherogenesis [10,11]. Thus, the study of autoimmune skin diseases as a model for understanding the systemic impact of localized immune responses on cardiovascular health underscores the importance of comprehensive care in patients with these conditions.

The intersection of immunodermatology and cardiovascular research has seen remarkable progress, largely attributed to technological advancements in the field of immunology and genomics. Recent innovations, such as single-cell RNA sequencing (scRNA-seq) and high-throughput immunophenotyping, have revolutionized our understanding of skin immunity and its implications for CVDs. Particularly, scRNA-seq has emerged as a powerful tool in immunodermatology, enabling researchers to dissect the complex cellular composition of the skin at an individual cell level. By cataloging the transcriptomes of thousands of cells, scRNA-seq facilitates the identification of distinct immune cell subsets, their functional states, and their interactions within the cutaneous environment [12]. This technology has uncovered previously unrecognized heterogeneity among skin-resident immune cells, including dendritic cells, macrophages, and T cells, and has highlighted the dynamic nature of these cells in health and disease [13,14,15]. For instance, scRNA-seq studies have identified specific T cell subsets enriched in psoriatic lesions, offering new insights into the pathogenesis of psoriasis and its association with increased cardiovascular risk [16].

High-throughput immunophenotyping complements scRNA-seq by providing detailed profiles of the surface markers and functional properties of immune cells at a population level. This approach, often coupled with flow cytometry or mass cytometry, allows for the simultaneous measurement of dozens of parameters, enabling a comprehensive analysis of the immune cell landscape in various tissues, including the skin [17]. This

has been instrumental in characterizing the systemic immune responses associated with CVDs, identifying key immune cell populations implicated in atherosclerosis and other cardiovascular conditions [18].

The integration of scRNA-seq and high-throughput immunophenotyping data has provided valuable insights into how skin-resident immune cells may influence systemic inflammation and contribute to the pathogenesis of CVDs. For example, studies have shown that certain skin-resident T cell subsets can secrete pro-inflammatory cytokines that have systemic effects, potentially exacerbating vascular inflammation and atherosclerosis [19,20,21]. Additionally, these technologies have identified potential biomarkers and therapeutic targets for CVDs, such as specific immune cell subsets or signaling pathways that are dysregulated in the context of skin inflammation and cardiovascular disease [16].

Moreover, emerging evidence suggests a potential role for the skin-gut axis in cardiovascular health. By analyzing the immune cell repertoires in the skin and gut, researchers have begun to unravel the complex interactions between these two organ systems and their collective impact on systemic inflammation and CVD risk [22]. The gut microbiota, which interacts closely with the immune system, has been implicated in the pathogenesis of CVD through its effects on systemic inflammation and metabolism. Interestingly, the skin microbiota may communicate with the gut microbiota through shared immune signaling pathways, influencing systemic immune responses and cardiovascular risk. For example, studies have demonstrated that alterations in the skin microbiome composition can lead to dysbiosis in the gut microbiota, which is associated with increased inflammation and atherosclerosis. Understanding the bidirectional communication between the skin and gut microbiota and its impact on cardiovascular health could provide novel insights into preventive and therapeutic strategies for CVD.

Furthermore, the role of environmental factors, such as ultraviolet (UV) radiation exposure, in modulating cutaneous immune responses and cardiovascular risk warrants further investigation. UV radiation, a potent immunomodulator, has been shown to affect various aspects of the immune system, including the function of cutaneous immune cells and the production of pro-inflammatory cytokines. Chronic UV exposure has been associated with skin inflammation, oxidative stress, and DNA damage, which may contribute to systemic inflammation and endothelial dysfunction, key mechanisms underlying CVD. Understanding the effects of UV radiation on cutaneous immunity and its implications for cardiovascular health could provide valuable insights into the development of targeted interventions for CVD prevention and management.

Areas for Future Research

Future research endeavors should focus on several key areas to advance our understanding of the role of cutaneous immune modulation in cardiovascular health and translate these findings into clinical practice. Firstly, more comprehensive studies are needed to identify the specific mechanisms through which cutaneous immune responses influence cardiovascular risk and disease progression. This may involve investigating the interactions between skin-derived inflammatory mediators, immune cells, and vascular endothelial cells in preclinical models and human cohorts. Additionally, large-scale epidemiological studies are warranted to establish the relationship between inflammatory skin conditions, such as psoriasis and atopic dermatitis, and cardiovascular outcomes, accounting for confounding variables such as traditional risk factors and systemic inflammation markers.

Furthermore, clinical trials evaluating the efficacy and safety of immunomodulatory therapies targeting the skin immune system in patients with or at risk of CVD are essential for guiding evidence-based clinical practice. These trials should assess the impact of interventions such as biologic agents, topical treatments, and lifestyle modifications on cardiovascular endpoints, including cardiovascular events, mortality, and quality of life. Moreover, studies investigating the role of the skin microbiota in cardiovascular health and evaluating the potential benefits of microbiome-targeted interventions, such as probiotics and microbial transplantation, are warranted. By addressing these research gaps, we can further study the complex interplay between the skin immune system and cardiovascular health and identify novel therapeutic strategies for preventing and managing CVD.

Conclusion

In conclusion, the emerging evidence linking cutaneous immune modulation to cardiovascular health underscores the importance of considering skin immunity as a potential target for preventive and therapeutic interventions in CVD. While preliminary studies have shown promising results, further research is needed to interpret the underlying mechanisms and validate the efficacy of immunomodulatory therapies targeting the skin in clinical settings. By bridging the gap between dermatology and cardiology and leveraging insights from skin immunology, we can develop innovative approaches for reducing cardiovascular risk and improving patient outcomes. Ultimately, integrating cutaneous immune modulation into cardiovascular disease management strategies has the potential to revolutionize preventive cardiology and enhance the quality of care for individuals at risk of CVD.

References

1. Ridker, P. M., Everett, B. M., & Thuren, T. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119-1131.
2. Ridker, P. M. (2019). Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis. Circulation Research, 124(3), 437-450.
3. Kupper, T. S., & Fuhlbrigge, R. C. (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nature Reviews Immunology, 4(3), 211-222.
4. Kong, H. H., Andersson, B., & Clavel, T. (2017). Performing skin microbiome research: a method to the madness. Journal of Investigative Dermatology, 137(3), 561-568.
5. Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology, 16(3), 143-155.
6. Feldman, S. R., Jiang, R., & Ortonne, J. P. (2019). Management of patients with hypertension and skin disease. Journal of the American Academy of Dermatology, 81(1), 1-13.

7. Shenoy, C., & Chawla, S. (2014). Diabetic dermopathy and diabetic foot ulcers: a review of current literature. International Journal of Diabetes in Developing Countries, 34(1), 58-63.
8. Schoenfeld, S. R., Kasturi, S., & Costenbader, K. H. (2013). The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. *Seminars in arthritis and rheumatism*, *43*(1), 77–95. https://doi.org/10.1016/j.semarthrit.2012.12.002
9. Ajeganova, S., Hafström, I., & Frostegård, J. (2021). Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years. *Lupus science & medicine*, *8*(1), e000454. https://doi.org/10.1136/lupus-2020-000454
10. Roman, M. J., Shanker, B. A., Davis, A., Lockshin, M. D., Sammaritano, L., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., & Salmon, J. E. (2003). Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *The New England journal of medicine*, *349*(25), 2399–2406. https://doi.org/10.1056/NEJMoa035471
11. Esdaile, J. M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R., Côte, R., Grover, S. A., Fortin, P. R., Clarke, A. E., & Senécal, J. L. (2001). Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis and rheumatism*, *44*(10), 2331–2337. https://doi.org/10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i
12. Theocharidis, G., Tekkela, S., Veves, A., McGrath, J. A., & Onoufriadis, A. (2022). Single-cell transcriptomics in human skin research: available technologies, technical considerations and disease applications. *Experimental dermatology*, *31*(5), 655–673. https://doi.org/10.1111/exd.14547
13. Liu, J., Chang, H. W., Huang, Z. M., Nakamura, M., Sekhon, S., Ahn, R., Munoz-Sandoval, P., Bhattarai, S., Beck, K. M., Sanchez, I. M., Yang, E., Pauli, M., Arron, S. T., Fung-Leung, W. P., Munoz, E., Liu, X., Bhutani, T., North, J., Fourie, A. M., Rosenblum, M. D., … Liao, W. (2021). Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. *The Journal of allergy and clinical immunology*, *147*(6), 2370–2380. https://doi.org/10.1016/j.jaci.2020.11.028
14. Hughes, T. K., Wadsworth, M. H., 2nd, Gierahn, T. M., Do, T., Weiss, D., Andrade, P. R., Ma, F., de Andrade Silva, B. J., Shao, S., Tsoi, L. C., Ordovas-Montanes, J., Gudjonsson, J. E., Modlin, R. L., Love, J. C., & Shalek, A. K. (2020). Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies. *Immunity*, *53*(4), 878–894.e7. https://doi.org/10.1016/j.immuni.2020.09.015
15. Cheng, J. B., Sedgewick, A. J., Finnegan, A. I., Harirchian, P., Lee, J., Kwon, S., Fassett, M. S., Golovato, J., Gray, M., Ghadially, R., Liao, W., Perez White, B. E., Mauro, T. M., Mully, T., Kim, E. A., Sbitany, H., Neuhaus, I. M., Grekin, R. C., Yu, S. S., Gray, J. W., … Cho, R. J. (2018). Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution. *Cell reports*, *25*(4), 871–883. https://doi.org/10.1016/j.celrep.2018.09.006
16. Mehta, N. N., Shin, D. B., Joshi, A. A., Dey, A. K., Armstrong, A. W., Duffin, K. C., Fuxench, Z. C., Harrington, C. L., Hubbard, R. A., Kalb, R. E., Menter, A., Rader, D. J., Reilly, M. P., Simpson, E. L., Takeshita, J., Torigian, D. A., Werner, T. J., Troxel, A. B., Tyring, S. K., Vanderbeek, S. B., … Gelfand, J. M. (2018). Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. *Circulation. Cardiovascular imaging*, *11*(6), e007394. https://doi.org/10.1161/CIRCIMAGING.117.007394
17. Leijten, E. F., van Kempen, T. S., Olde Nordkamp, M. A., Pouw, J. N., Kleinrensink, N. J., Vincken, N. L., Mertens, J., Balak, D. M. W., Verhagen, F. H., Hartgring, S. A., Lubberts, E., Tekstra, J., Pandit, A., Radstake, T. R., & Boes, M. (2021). Tissue-Resident Memory CD8+ T Cells from Skin Differentiate Psoriatic Arthritis from Psoriasis. *Arthritis & rheumatology (Hoboken, N.J.)*, *73*(7), 1220–1232. https://doi.org/10.1002/art.41652
18. Winkels, H., Ehinger, E., Vassallo, M., Buscher, K., Dinh, H. Q., Kobiyama, K., Hamers, A. A. J., Cochain, C., Vafadarnejad, E., Saliba, A. E., Zernecke, A., Pramod, A. B., Ghosh, A. K., Anto Michel, N., Hoppe, N., Hilgendorf, I., Zirlik, A., Hedrick, C. C., Ley, K., & Wolf, D. (2018). Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry. *Circulation research*, *122*(12), 1675–1688. https://doi.org/10.1161/CIRCRESAHA.117.312513
19. Strobl, J., Gail, L. M., Kleissl, L., Pandey, R. V., Smejkal, V., Huber, J., Puxkandl, V., Unterluggauer, L., Dingelmaier-Hovorka, R., Atzmüller, D., Krausgruber, T., Bock, C., Wohlfarth, P., Rabitsch, W., & Stary, G. (2021). Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. *The Journal of experimental medicine*, *218*(11), e20210417. https://doi.org/10.1084/jem.20210417
20. Li, G., Larregina, A. T., Domsic, R. T., Stolz, D. B., Medsger, T. A., Jr, Lafyatis, R., & Fuschiotti, P. (2017). Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. *The Journal of investigative dermatology*, *137*(5), 1042–1050. https://doi.org/10.1016/j.jid.2016.11.037
21. Baumer, Y., Ng, Q., Sanda, G. E., Dey, A. K., Teague, H. L., Sorokin, A. V., Dagur, P. K., Silverman, J. I., Harrington, C. L., Rodante, J. A., Rose, S. M., Varghese, N. J., Belur, A. D., Goyal, A., Gelfand, J. M., Springer, D. A., Bleck, C. K., Thomas, C. L., Yu, Z. X., Winge, M. C., … Mehta, N. N. (2018). Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. *JCI insight*, *3*(1), e97179. https://doi.org/10.1172/jci.insight.97179
22. Reali, E., Caliceti, C., Lorenzini, A., & Rizzo, P. (2024). The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity. *Inflammation*, *47*(1), 13–29. https://doi.org/10.1007/s10753-023-01915-1